EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN
Authors:
- Yong HuangYHYong Huang
- Lynda FrassettoLFLynda Frassetto
- Leslie Z. BenetLBLeslie Z. Benet
- 1 November 2004
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 32 (11) , 1239-1246
Abstract
Hepatic clearance of erythromycin (Ery) is significantly reduced in patients with end stage renal disease. Since Ery is primarily eliminated via excretion of unchanged drug in the bile, we suspect that this change could be due to the effect of uremic toxins on hepatic uptake and/or efflux transporters. Using rat hepatocytes and microsomes as model proof of concept systems, we examined six uremic toxins, 3-carboxy-4-methyl-5-propyl-2-furan-propanoic acid (CMPF), indoxyl sulfate (IS), hippuric acid (HA), indole acetic acid (IA), guanidinosuccinic acid (GSA), and indoxyl-β-d-glucuronide (IG), for their effects on Ery uptake and metabolism. Ery and the metabolite N-demethyl-Ery were measured by liquid chromatography/tandem mass spectrometry. The uptake of Ery by rat hepatocytes was markedly inhibited by rifampin and digoxin, but not by quinidine, suggesting that Oatp2 plays a major role in the uptake of Ery. At 50 μM, CMPF significantly (p < 0.05) reduced hepatocyte accumulation of Ery and N-demethyl-Ery. At higher concentrations (>200 μM), CMPF appears to also inhibit the enzymatic metabolism of Ery. In contrast, IS did not significantly inhibit the hepatocyte uptake of Ery, even at the highest concentration (800 μM) tested, but reduced metabolite generation (p < 0.001). The other uremic toxins, HA, IA, IG, and GSA, did not affect either hepatic uptake or microsomal metabolism of Ery. CMPF, IS, and HA were shown not to inhibit differential P-glycoprotein transport of Ery in cellular systems. Our results suggest that CMPF can directly inhibit the uptake of Ery by inhibiting Oatp2, whereas IS is more likely to inhibit the enzymatic metabolism of Ery.Keywords
This publication has 37 references indexed in Scilit:
- Characterization of hepatic cytochrome P4503A activity in patients with end‐stage renal diseaseClinical Pharmacology & Therapeutics, 2003
- The Effect of Chronic Renal Failure on Hepatic Drug Metabolism and Drug DispositionSeminars in Dialysis, 2003
- The superfamily of organic anion transporting polypeptidesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2003
- Drug transport proteins in the liverAdvanced Drug Delivery Reviews, 2003
- Down‐regulation of hepatic cytochrome P450 in chronic renal failure: role of uremic mediatorsBritish Journal of Pharmacology, 2002
- Identification of Thyroid Hormone Transporters in Humans: Different Molecules Are Involved in a Tissue-Specific MannerEndocrinology, 2001
- Expression cloning of a rat liver Na(+)-independent organic anion transporter.Proceedings of the National Academy of Sciences, 1994
- Reduced hepatic uptake of propranolol in rats with acute renal failureBiochemical Pharmacology, 1985
- Pharmacokinetics and biliary excretion of bromosulphophthalein, [3H]-ouabain and [3H]-taurocholic acid in rats with glycerol-induced acute renal failureBritish Journal of Pharmacology, 1984
- Pharmacokinetics of cefotaxime in subjects with normal and impaired renal functionJournal of Antimicrobial Chemotherapy, 1980